Search | Clinical Trials Finder

Conditions: Pachyonychia Congenita
Interventions: QTORIN 3.9% rapamycin anhydrous gel, Vehicle; Drug
Lead sponsor: Palvella Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Palo Alto, California • New Haven, Connecticut • Orange Park, Florida + 4 more

Conditions: Ulcerative Colitis
Interventions: APL-1401, Placebo; Drug
Lead sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Corona, California • Tampa, Florida • Marrero, Louisiana + 1 more

Conditions: Lupus Nephritis
Interventions: secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Birmingham, Alabama • Fontana, California • Los Angeles, California + 5 more

Conditions: Friedreich Ataxia
Interventions: TAK-831, TAK-831 Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 3 more

Conditions: Peanut Allergy
Interventions: Whole peanut extract, Placebo formulation; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 6 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more

Conditions: Heart Failure With Normal Ejection Fraction
Interventions: Anakinra, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Complicated Intra-abdominal Infection
Interventions: CXA-101/ tazobactam and metronidazole, meropenem plus saline placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 90 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Orange, California • Torrance, California • Aurora, Colorado + 8 more

Conditions: Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 22
States / cities: Miramar, Florida • Orlando, Florida • Conyers, Georgia + 19 more

Conditions: Rheumatoid Arthritis
Interventions: Tasocitinib plus Methotrexate, Tofacitinib plus placebo methotrexate, Placebo tofacitinib plus Methotrexate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more

Conditions: Insomnia
Interventions: Placebo ethanol, Ethanol, Placebo, Gabapentin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Idiopathic Constipation
Interventions: Plecanatide, Matching placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 36
States / cities: Foley, Alabama • Jonesboro, Arkansas • Cerritos, California + 33 more

Conditions: Dyslipidemia
Interventions: JTT-302, Placebo; Drug
Lead sponsor: Akros Pharma Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Santa Ana, California

Conditions: Hereditary Periodic Fevers
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Month and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio

Conditions: Prosthetic Joint Infection
Interventions: Phage Therapy, Two-Stage Exchange Arthroplasty; Biological · Procedure
Lead sponsor: Adaptive Phage Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Critical Limb Ischemia
Interventions: HGF Plasmid (AMG0001), Matching Placebo; Biological
Lead sponsor: AnGes USA, Inc.; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 28
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 23 more

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions: Placebo, Linaclotide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 52
States / cities: Huntsville, Alabama • North Little Rock, Arkansas • Phoenix, Arkansas + 49 more

Conditions: Rheumatoid Arthritis
Interventions: Leflunomide, Methotrexate, Ocrelizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 144
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more

Conditions: Neurodermatitis
Interventions: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more

Conditions: Mantle-Cell Lymphoma
Interventions: Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 14
States / cities: Tucson, Arizona • Duarte, California • Los Angeles, California + 10 more

Conditions: Irritable Bowel Syndrome
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Rochester, Minnesota • La Crosse, Wisconsin

Conditions: Cystitis, Interstitial, Painful Bladder Syndrome
Interventions: LiRIS®, LiRIS Placebo; Combination Product
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 31
States / cities: Mobile, Alabama • Escondido, California • Los Angeles, California + 27 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 3 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Madera, California • Ventura, California • Aurora, Colorado + 11 more

Conditions: Alzheimer's Disease
Interventions: E2212, placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Santa Barbara, California • Gainesville, Florida + 8 more

Search by objective public record fields.

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

Interleukin-1 Blockade in HF With Preserved EF

Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Bacteriophage Therapy in Patients With Prosthetic Joint Infections

Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)